domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -19,22 +19,28 @@ The competitive dynamics (Lilly vs. Novo vs. generics post-2031) will drive pric
 
 
 ### Additional Evidence (extend)
-*Source: [[2024-08-01-jmcp-glp1-persistence-adherence-commercial-populations]] | Added: 2026-03-15 | Extractor: anthropic/claude-sonnet-4.5*
+*Source: 2024-08-01-jmcp-glp1-persistence-adherence-commercial-populations | Added: 2026-03-15 | Extractor: anthropic/claude-sonnet-4.5*
 
 Real-world persistence data from 125,474 commercially insured patients shows the chronic use model fails not because patients choose indefinite use, but because most cannot sustain it: only 32.3% of non-diabetic obesity patients remain on GLP-1s at one year, dropping to approximately 15% at two years. This creates a paradox for payer economics—the "inflationary chronic use" concern assumes sustained adherence, but the actual problem is insufficient persistence. Under capitation, payers pay for 12 months of therapy ($2,940 at $245/month) for patients who discontinue and regain weight, capturing net cost with no downstream savings from avoided complications. The economics only work if adherence is sustained AND the payer captures downstream benefits—with 85% discontinuing by two years, the downstream cardiovascular and metabolic savings that justify the cost never materialize for most patients.
 
 
 ### Additional Evidence (extend)
-*Source: [[2025-06-01-cell-med-glp1-societal-implications-obesity]] | Added: 2026-03-15*
+*Source: 2025-06-01-cell-med-glp1-societal-implications-obesity | Added: 2026-03-15*
 
 The Cell Press review characterizes GLP-1s as marking a 'system-level redefinition' of cardiometabolic management with 'ripple effects across healthcare costs, insurance models, food systems, long-term population health.' Obesity costs the US $400B+ annually, providing context for the scale of potential cost impact. The WHO issued conditional recommendations within 2 years of widespread adoption (December 2025), unusually fast for a major therapeutic category.
 
 
 ### Additional Evidence (extend)
-*Source: [[2025-03-01-medicare-prior-authorization-glp1-near-universal]] | Added: 2026-03-15*
+*Source: 2025-03-01-medicare-prior-authorization-glp1-near-universal | Added: 2026-03-15*
 
 MA plans' near-universal prior authorization creates administrative friction that may worsen the already-poor adherence rates for GLP-1s. PA requirements ensure only T2D-diagnosed patients can access, effectively blocking obesity-only coverage despite FDA approval. This access restriction compounds the chronic-use economics challenge by adding administrative barriers on top of existing adherence problems.
 
+
+### Additional Evidence (challenge)
+*Source: [[2025-01-01-select-cost-effectiveness-analysis-obesity-cvd]] | Added: 2026-03-16*
+
+SELECT trial cost-effectiveness analysis shows semaglutide achieves $32,219/QALY at 48% rebated prices (highly cost-effective) versus $136,271/QALY at list price (borderline). Recent Medicare pricing at $245/month and Trump-negotiated deals represent 82% discounts from list, placing actual ICERs well below cost-effectiveness thresholds. The declining price trajectory may flip GLP-1s from net inflationary to cost-saving before 2035.
+
 ---
 
 Relevant Notes:

domains/health/federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings.md

@@ -41,10 +41,16 @@ The claim that budget scoring "systematically" undervalues prevention requires e
 
 
 ### Additional Evidence (confirm)
-*Source: [[2024-11-01-aspe-medicare-anti-obesity-medication-coverage]] | Added: 2026-03-16*
+*Source: 2024-11-01-aspe-medicare-anti-obesity-medication-coverage | Added: 2026-03-16*
 
 The CBO vs. ASPE divergence on Medicare GLP-1 coverage provides concrete evidence: CBO projects $35B in additional spending (2026-2034) using budget scoring methodology, while ASPE projects net savings of $715M over 10 years using clinical economics methodology that includes downstream event avoidance. The $35.7B gap between these estimates demonstrates how budget scoring rules structurally disadvantage preventive interventions. CBO uses conservative uptake assumptions and doesn't fully count avoided hospitalizations and disease progression within the 10-year window, while ASPE includes 38,950 CV events avoided and 6,180 deaths avoided. Both are technically correct but answer different questions—budget impact vs. clinical economics.
 
+
+### Additional Evidence (confirm)
+*Source: [[2025-01-01-select-cost-effectiveness-analysis-obesity-cvd]] | Added: 2026-03-16*
+
+SELECT lifetime horizon model shows average per-subject treatment cost of $47,353 generates $18,017 in savings from avoided complications ($14,431 T2D + $2,074 CKD + $1,512 CV), but these savings accrue over decades. A 10-year budget window would capture treatment costs but miss majority of prevention savings, systematically biasing against GLP-1 coverage expansion.
+
 ---
 
 Relevant Notes:

domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md

@@ -32,10 +32,16 @@ For value-based care models and capitated payers, this multi-organ protection cr
 
 
 ### Additional Evidence (extend)
-*Source: [[2025-12-23-jama-cardiology-select-hospitalization-analysis]] | Added: 2026-03-16*
+*Source: 2025-12-23-jama-cardiology-select-hospitalization-analysis | Added: 2026-03-16*
 
 SELECT trial exploratory analysis (N=17,604, median 41.8 months) shows semaglutide reduces ALL-CAUSE hospitalizations by 10% (18.3 vs 20.4 per 100 patient-years, P<.001) and total hospital days by 11% (157.2 vs 176.2 days per 100 patient-years, P=.01). Critically, benefits extended beyond cardiovascular causes to total hospitalization burden, suggesting systemic effects across multiple organ systems.
 
+
+### Additional Evidence (extend)
+*Source: [[2025-01-01-select-cost-effectiveness-analysis-obesity-cvd]] | Added: 2026-03-16*
+
+SELECT economic model quantifies the relative value of multi-organ protection: T2D prevention generates $14,431 per-patient savings, CKD prevention $2,074, and CV events only $1,512. Diabetes prevention is the dominant economic lever, not cardiovascular protection, even in a CVD population.
+
 ---
 
 Relevant Notes:

inbox/archive/.extraction-debug/2025-01-01-select-cost-effectiveness-analysis-obesity-cvd.json

@@ -0,0 +1,32 @@
+{
+  "rejected_claims": [
+    {
+      "filename": "glp-1-cost-effectiveness-depends-on-net-price-not-list-price-with-4x-variation-in-icer.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    },
+    {
+      "filename": "glp-1-diabetes-prevention-savings-exceed-cardiovascular-savings-by-10x-per-patient.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    }
+  ],
+  "validation_stats": {
+    "total": 2,
+    "kept": 0,
+    "fixed": 2,
+    "rejected": 2,
+    "fixes_applied": [
+      "glp-1-cost-effectiveness-depends-on-net-price-not-list-price-with-4x-variation-in-icer.md:set_created:2026-03-16",
+      "glp-1-diabetes-prevention-savings-exceed-cardiovascular-savings-by-10x-per-patient.md:set_created:2026-03-16"
+    ],
+    "rejections": [
+      "glp-1-cost-effectiveness-depends-on-net-price-not-list-price-with-4x-variation-in-icer.md:missing_attribution_extractor",
+      "glp-1-diabetes-prevention-savings-exceed-cardiovascular-savings-by-10x-per-patient.md:missing_attribution_extractor"
+    ]
+  },
+  "model": "anthropic/claude-sonnet-4.5",
+  "date": "2026-03-16"
+}

inbox/archive/2025-01-01-select-cost-effectiveness-analysis-obesity-cvd.md

@@ -7,9 +7,13 @@ date: 2025-01-01
 domain: health
 secondary_domains: [internet-finance]
 format: paper
-status: unprocessed
+status: enrichment
 priority: medium
 tags: [glp-1, semaglutide, cost-effectiveness, cardiovascular, SELECT-trial, QALY]
+processed_by: vida
+processed_date: 2026-03-16
+enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -43,3 +47,10 @@ Cost-effectiveness analysis of semaglutide 2.4mg based on SELECT trial data, mod
 PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
 WHY ARCHIVED: Cost-effectiveness is price-dependent — the declining price trajectory may flip GLP-1s from inflationary to cost-effective faster than the existing claim anticipates
 EXTRACTION HINT: Focus on the price sensitivity of the cost-effectiveness conclusion and how recent price deals change the math
+
+
+## Key Facts
+- SELECT trial per 100,000 subjects treated (lifetime): 2,791 non-fatal MIs avoided, 3,000 revascularizations avoided, 487 strokes avoided, 115 CV deaths avoided
+- Australian cost-effectiveness analysis: A$96,055/QALY at A$4,175/year pricing, not cost-effective at A$50,000/QALY threshold
+- ICER 2025 assessment: semaglutide and tirzepatide now meet <$100K/QALY at net prices (shift from 2022 assessment)
+- Study funded by Novo Nordisk with 48% rebate assumption based on their internal net pricing estimates